Kmpharmaceutical KRX:225430KOSDAQ
케이엠제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h4
Articles, 7 days15
DART filings, 7 days7
Articles tracked15since Sep 11
In Q2 2026, Kmpharmaceutical reported revenue of ₩3.8bn, up 18.4% year on year, and an operating loss of ₩585m. Kmpharmaceutical (케이엠제약) appeared in 15 Korean news articles and 7 DART filings over the past seven days. Coverage peaked on Sep 15 with 6 articles. The most common catalyst was risk & warnings (5). It was most often mentioned alongside SK biopharmaceuticals.
Filing signals 4 quarters of losses Delisting / halt risk Screener
Kmpharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩3.8bn | +18.4% | −₩585m | −₩757m |
| Q1 2026 | ₩4.5bn | +9.5% | −₩659m | −₩834m |
| Q4 2025 derived | ₩4.3bn | +26.4% | −₩851m | −₩1.2bn |
| Q3 2025 | ₩4.4bn | +32.7% | −₩809m | −₩1.0bn |
| Q2 2025 | ₩3.2bn | -2.2% | −₩721m | −₩964m |
| Q1 2025 | ₩4.1bn | -8.7% | −₩542m | −₩824m |
| Q4 2024 derived | ₩3.4bn | -2.0% | −₩470m | −₩1.9bn |
| Q3 2024 | ₩3.3bn | -18.5% | −₩753m | −₩950m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Kmpharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Kmpharmaceutical news Korean headlines
-
‘상폐 통보’ 케이엠제약 上…SK바이오팜은 FDA 보류에↓[바이오 맥짚기]
1 more on this story · 1 outlets
- ‘상폐 통보’ 케이엠제약 上…SK바이오팜은 FDA 보류에↓[바이오 맥짚기]이데일리 · Sep 15 08:28